The President of COREE Group,
Chongyoon-Lim, signed a "Special Fund for the Prevention and Treatment of
Metabolic Diseases" with Peking Union Medical Foundation.
It covers GDM and more specific, broader
research protocols.
On November 15, 2019, Peking Union Medical
Foundation-COREE Group (an affiliate of Hanmi Pharmaceutical Group) Metabolic
Diseases Prevention and Treatment Research Special Fund was officially
announced.
The Special Fund aims to further improve
the prevention and treatment of maternal and infant metabolic diseases, reduce
birth defects and protect maternal and infant health. The signing ceremony was
held at the Telemedicine Center of Peking Union Medical College Hospital,
Chairman of Peking Union Medical Foundation Jiang Yu-xin, Professor of
Obstetrics and Gynecology in Peking Union Medical College Hospital Xu Ling, the
Head of the Special Fund Ma Liangkun, Founder of COREE Group Chongyoon-Lim
(President of Korean Biological Association and Representative Director of
Hanmi Group), the Head of COREE Group, and other relevant representatives
attended the signing ceremony.
The COREE Group, founded by Representative
Chongyoon-Lim of Hanmi Science, is a global company with subsidiaries in Asia,
Europe and the Americas that conducts research, investment and expands new
business orientations. COREE Group owns the Bio-Health Consulting Systems
"COREE Therapeutics" and "Therapy R&D Center" developed
in cooperation with world-class hospitals and global medical experts. The
world's first Biobank "MOTHER AND CHILD AND BEYOND BIO BANK" for
puerpera and children was established in China and Italy in 2017.
Peking Union Medical Foundation-COREE Group
Metabolic Disease Prevention and Treatment and Research Special Fund mainly
studies on maternal and infant metabolic diseases pathogenesis, maternal and
infant metabolic diseases genetic correlation and maternal and infant metabolic
diseases prevention and treatment programs.
Especially for Gestational Diabetes
Mellitus (GDM), which has not been identified as the reason why drug treatment
cannot be carried out during pregnancy, the fundamental treatment and research
should be carried out.
Pregnant women with GDM account for about
10% of pregnant women. So the research and treatment of it need to be paid
attention at the early diagnosis of disease. The report indicates that if GDM
is not treated, children are more likely to develop metabolic diseases in the
future. The aim of the joint study is to renovate technologies that could be
used to treat GDM without drug treatment for maternal and infant.
COREE Group and Peking Union Medical
Foundation will promote the innovation model of mobile medical service in
maternal and infant field and construct the maternal and infant health database
at the same time.
Beijing Hanmi Pharmaceuticals represented
by Ofmom, the core brand of "BIO South Korean Trend", led by
Representative Chongyoon-Lim, has joined hands with COREE Group to make the
prospect of this cooperation even more worthy of expectation. The industry
forecasts that COREE Group, Hanmi Science and Beijing Hanmi
pharmaceutical-related pharmaceutical production and "Personalized
Therapy" proposed by Representative Chongyoon-Lim will become a new
medical innovation model in the future.
The Head of the COREE Group stated: The
collaborative study is a program for the prevention and treatment of metabolic
diseases focusing on maternal and child.
The establishment of the Special Fund will
introduce specific mass medical services and prevention and treatment
interventions, for which purpose information is being obtained on the
application of medical insurance. If health management during pregnancy and
childbirth, growth (including the prevention and treatment of metabolic
diseases such as GDM etc.) can be covered by health insurance, which will have
a positive impact research on low fertility, diabetes and obesity, and
metabolic diseases. Therefore, communication and applications are being planned
with the relevant authorities.
